Bioxcel Therapeutics Inc (BTAI)
NASDAQ:BTAI
Total Valuation
Bioxcel Therapeutics has a market cap or net worth of $29.78M. The enterprise value is $110.96M.
Market Cap$29.78M
Enterprise Value$110.96M
Share Statistics
Bioxcel Therapeutics has 27,074,587 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding27,074,587
Owned by Insiders3.25%
Owned by Institutions1.35%
Financial Efficiency
Bioxcel Therapeutics’s return on equity (ROE) is 0.73 and return on invested capital (ROIC) is -312.20%.
Return on Equity (ROE)0.73
Return on Assets (ROA)-1.56
Return on Invested Capital (ROIC)-312.20%
Return on Capital Employed (ROCE)5.52
Revenue Per Employee17.35K
Profits Per Employee-1.89M
Employee Count37
Asset Turnover0.01
Inventory Turnover0.64
Valuation Ratios
The current PE Ratio of Bioxcel Therapeutics is ―. Bioxcel Therapeutics’s PEG ratio is 0.00370.
PE Ratio―
PS Ratio30.42
PB Ratio-0.20
Price to Fair Value-0.20
Price to FCF-0.34
Price to Operating Cash Flow-0.23
PEG Ratio0.00370
Income Statement
In the last 12 months, Bioxcel Therapeutics had revenue of 642.00K and earned -69.90M in profits. Earnings per share was -5.73.
Revenue642.00K
Gross Profit178.00K
Operating Income-49.70M
Pretax Income-69.90M
Net Income-69.90M
EBITDA-49.41M
Earnings Per Share (EPS)-5.73
Cash Flow
In the last 12 months, operating cash flow was -57.62M and capital expenditures 0.00, giving a free cash flow of -57.62M billion.
Operating Cash Flow-57.62M
Free Cash Flow-57.62M
Free Cash Flow per Share-2.13
Dividends & Yields
Bioxcel Therapeutics pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta2.19
52-Week Price Change-38.55%
50-Day Moving Average1.52
200-Day Moving Average2.25
Relative Strength Index (RSI)32.61
Average Volume (3m)1.58M
Important Dates
Bioxcel Therapeutics upcoming earnings date is May 11, 2026, TBA (Confirmed).
Last Earnings DateMar 27, 2026
Next Earnings DateMay 11, 2026
Ex-Dividend Date―
Financial Position
Bioxcel Therapeutics as a current ratio of 0.83, with Debt / Equity ratio of -114.80%
Current Ratio0.83
Quick Ratio0.82
Debt to Market Cap5.61
Net Debt to EBITDA-1.64
Interest Coverage Ratio-2.93
Taxes
In the past 12 months, Bioxcel Therapeutics has paid 0.00 in taxes.
Income Tax0.00
Effective Tax Rate0.00
Enterprise Valuation
Bioxcel Therapeutics EV to EBITDA ratio is -2.04, with an EV/FCF ratio of -1.75.
EV to Sales156.87
EV to EBITDA-2.04
EV to Free Cash Flow-1.75
EV to Operating Cash Flow-1.75
Balance Sheet
Bioxcel Therapeutics has $28.41M in cash and marketable securities with $109.59M in debt, giving a net cash position of -$81.18M billion.
Cash & Marketable Securities$28.41M
Total Debt$109.59M
Net Cash-$81.18M
Net Cash Per Share-$3.00
Tangible Book Value Per Share-$7.82
Margins
Gross margin is 51.25%, with operating margin of -7742.21%, and net profit margin of -10887.38%.
Gross Margin51.25%
Operating Margin-7742.21%
Pretax Margin-10887.38%
Net Profit Margin-10887.38%
EBITDA Margin-7695.48%
EBIT Margin-7742.21%
Analyst Forecast
The average price target for Bioxcel Therapeutics is $7.67, which is 11.43% higher than the current price. The consensus rating is Moderate Buy
Price Target$7.67
Price Target Upside597.27% Upside
Analyst ConsensusModerate Buy
Analyst Count3
Revenue Growth Forecast-66.96%
EPS Growth Forecast71.83%